IMA203, a PRAME-targeting TCR-T cell therapy, in PD1-refractory melanoma скачать в хорошем качестве

IMA203, a PRAME-targeting TCR-T cell therapy, in PD1-refractory melanoma

Martin Wermke, MD, TU Dresden University of Technology, Dresden, Germany, discusses a Phase I trial (NCT03686124) of IMA203, a PRAME-targeting autologous TCR-T cell therapy, in patients with PD-1-refractory metastatic melanoma. IMA203 demonstrated a favorable safety profile, with mainly low-grade cytokine release syndrome and limited neurotoxicity. Encouraging antitumor activity was observed across multiple metastatic sites, particularly at higher doses. Confirmed responses appeared durable, with many ongoing beyond one year. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.